Psychiatric comorbidity in a cohort of heroin and amphetamine users in Perth, Western Australia

Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019

INTRODUCTION

Amphetamine type substances (ATS) are commonly used by Australian alcohol and other drug service entrants. We describe demographic characteristics, patterns of ATS and other substance use, health and social conditions among clients entering New South Wales (NSW) public alcohol and other drug services.

METHODS

Retrospective cohort of 13,864 records across six health districts (2016-2019) for clients seeking substance use treatment. These districts service approximately 44% of the NSW population aged 15 years and over. Multivariate analysis was conducted on a subsample for whom full data were available (N = 9981). Data included NSW Minimum Data Set for drug and alcohol treatment services and Australian Treatment Outcomes Profile items.

RESULTS

Over the preceding 4 weeks, 77% (n = 10,610) of clients (N = 13,864) reported no recent ATS use, 15% (n = 2109) reported 'low frequency' (1-12 days) and 8% (n = 1145) 'high frequency' (13-28 days) use. ATS use was most common among people attending for ATS or opioids as primary drug of concern. A multinomial regression (N = 9981) identified that clients reporting recent arrest (aOR 1.74, 95% CI 1.36, 2.24), higher cannabis use frequency (aOR 1.01, 95% CI 1.00, 1.02), lower opioid use frequency (aOR 0.98, 95% CI 0.97, 0.99) and poorer quality of life (aOR 0.91, 95% CI 0.86, 0.97) were more likely to report 'high frequency' rather than 'low frequency' ATS use.

DISCUSSION AND CONCLUSIONS

People who use ATS experience health and social issues that may require targeted responses. These should be integrated across all services, not only for clients with ATS as principal drug of concern.

Morbidity associated with amphetamine-related presentations to an emergency department: A record linkage study

OBJECTIVE

Amphetamine use is a global public health problem. We examined hospitalisations in a cohort of 138 patients who presented with an amphetamine-related problem to an ED in 2005.

METHODS

A record linkage study, using the morbidity, ED and mortality databases in the Data Linkage Unit of the Department of Health, Western Australia. The main outcome measures were hospital separations and length of stay (LOS) 5 years before and 4 years after entry into the cohort.

RESULTS

One hundred and thirty patients (94%) with an amphetamine-related presentation had a link with the hospital morbidity dataset. The most common diagnosis before and after cohort entry was mental disorders (before: F00-F99; 405 separations, total LOS 2570 days; after: 309 separations, total LOS 3671 days). Injury and poisoning was the next most common in both time periods. Men had an increased relative risk (RR) for all days of psychiatric care (RR 2.12, 95% CI 1.04-4.35). After adjusting for age and sex, the highest risks of increased LOS occurred within 1 year before (RR 2.22, 95% CI 1.01-4.91) and 2 years post entry into the cohort (RR 4.21, 95% CI 1.87-9.46 and RR 2.82, 95% CI 1.25-6.34). There were four (2.9%, 95% CI 0.9-7.7%) deaths, which occurred within 2 years post cohort entry.

CONCLUSION

Amphetamine-related presentations to the ED are associated with a significant cluster of hospitalisations around that episode. This is most prominent for psychiatric diagnoses, with a large increase in the total LOS in the year following cohort entry. Counselling less risky behaviour might decrease the burden of illness.

Treatment approaches for dual diagnosis clients in England

INTRODUCTION

Dual diagnosis (DD, co-occurrence of substance use and mental health problems) prevalence data in England are limited to specific regions and reported rates vary widely. Reliable information on actual service provision for dual diagnosis clients has not been collated. Thus a national survey was carried out to estimate dual diagnosis prevalence in treatment populations and describe the service provision available for this client population in drug/alcohol (DAS) and mental health services (MHS).

DESIGN

A questionnaire was sent to managers of 706 DAS and 2374 MHS. Overall, 249 (39%) DAS and 493 (23%) MHS participated in the survey.

RESULTS

In both DAS and MHS, around 32% of clients were estimated to have dual diagnosis problems. However, fewer than 50% of services reported assessing clients for both problem areas. Regarding specific treatment approaches, most services (DAS: 88%, MHS: 87%) indicated working jointly with other agencies. Significantly fewer services used joint protocols (DAS: 55%, MHS: 48%) or shared care arrangements, including access to external drug/alcohol or mental health teams (DAS: 47%, MHS: 54%). Only 25% of DAS and 17% of MHS employed dual diagnosis specialists.

CONCLUSIONS

Dual diagnosis clients constitute a substantial proportion of clients in both DAS and MHS in England. Despite recent policy initiatives, joint working approaches tend to remain unstructured.